| INTRODUCTION
There is clear evidence that vascular smooth muscle cells (VSMCs) proliferation is a key step in the progression of atherosclerosis, intimal hyperplasia and hypertension.
1 VSMCs can be converted from the contractile phenotype to the synthetic phenotype under physiological and pathological conditions, such as vascular injury, mechanical stretch and growth factor stimulation. The VSMCs phenotypic modulation is beneficial for VSMCs proliferation and a robust factor in the development of proliferative vascular diseases. response partly via a TLR4-dependent signalling pathway in VSMCs. 6 Inflammation is a major event in the process of atherosclerosis and restenosis after vascular injury. 7 LPS, often referred to as endotoxin from Gram-negative bacteria, is a mitogen of sepsis. It is composed of three structural elements: a core oligosaccharide, an O-antigen and a lipid A. Marshall reported that LPS mediation actions could be modulated at multiple levels. 8 The LPS from different bacteria do the same role on cells. 19, 20 In this review, we will summarize the remarkable effects and molecular mechanisms of LPS in VSMCs proliferation. In addition, the potential inhibitors of TLR4 signalling for VSMCs proliferation in proliferative vascular diseases will be discussed.
| MECHANISMS AND POTENTIAL SIGNALLING PATHWAYS
It is well-known that LPS-stimulated TLR4 activation involves many signal cascade reactions; including phosphatidylinositol 3-kinase/Akt (PI3K/Akt), mitogen-activated protein kinase (MAPK s) and interleukin-1 receptor-associated kinase (IRAKs), and all of these pathways involve cell proliferation. The precise molecular mechanisms by which these signalling pathways are involved in VSMCs proliferation induced by LPS are in need of further clarification.
| LPS and the PI3K/Akt signalling pathway
As a major transducer of mitogenic signals in a variety of cells, Akt is activated by arterial injury and contributes to neointimal formation.
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Akt is a main downstream effector of PI3K-mediated cell survival, and the PI3K/Akt signalling pathway is required for VSMCs proliferation. Inhibition of the PI3K/Akt signalling pathway has been shown to limit neointimal formation in rat vascular injury models. Hattori Phosphorylation of Ser473 and Thr308 sites is essential for Akt activation, which is involved in VSMCs proliferation associated with inflammatory stimuli, such as AngII and PDGF in vitro and mechanical vascular injury in vivo. A previous study has suggested that LPS induced lung fibroblast proliferation through TLR4 signalling and the PI3K/Akt signalling pathway. 23 Our previous study has shown p-Akt expression after LPS stimulation in rat VSMCs. 24 In our experiments, VSMCs were stimulated with LPS for 24 hours before cell counts and the 5-ethynyl-2-deoxyuridine (EdU) staining assays. These results
showed that pre-incubation with LY294002 partially blocked VSMCs proliferation stimulated by LPS. Moreover, Western blotting demonstrated that the levels of p-Akt (308) and p-Akt (473) protein expression were up-regulated and achieved a peak 60 minutes after LPS stimulation. Taken together, these results suggest that the PI3K/Akt pathway mediates VSMCs proliferation after LPS stimulation.
| LPS and the Rac1 signalling pathway
The previous study has summarized the role of Ras-related C3 botulinum toxin substrate 1 (Rac1) in cardiovascular and cerebrovascular diseases. 25 It has been reported that Rac1 promotes pulmonary artery VSMCs proliferation, 26 and is essential in mediating VSMCs proliferation induced by PDGF in rats. It has been reported that LPS treatment rapidly induces the activation of Rac1 in a time-dependent manner in
VSMCs. 27 Because Rac1 is involved in cell proliferation, we evaluate whether Rac1 is also required for LPS-induced VSMCs proliferation. 24 As seen in our previous study, 24 VSMCs were stimulated with LPS for 
| LPS and the mitogen-activated protein kinases signalling pathway
As a classical signalling pathway, MAPKs are involved in cardiovascular disorders. 28 MAPKs are phosphorylated on serine and tyrosine residues by dual-specific kinases. The kinase family has three members, including ERKs, c-jun N terminal kinase/stress-activated protein kinases (JNK/SAPKs) and the protein kinase, p38. Downstream effectors of MAPKs, including ERK1/2, JNK1/2 and p38MAPK, are rapidly activated by balloon injury in rat carotid arteries. 29 The proliferative effect of the MAPKs pathway in VSMCs is an increasing concern.
Kim investigated the effects of TLR4 signalling and the involvement 
| LPS and the IRAKs signalling pathway
It is well-known that activity of IRAK1 and IRAK4 kinases is indispensable in TLR signalling. has reported that the expression of ssc-miR-146a-5p and ssc-miR-221-5p is up-regulated in pig skeletal muscle after LPS stimulation.
| LPS and MicroRNAs
Wang has reported that the expression of miR-152 is down-regulated in LPS-stimulated VSMCs. The over-expression of miR-152 decreases VSMCs proliferation stimulated by LPS. 41 As new regulators of TLR, further investigations should focus on the potential function of miRNAs in VSMCs proliferation induced by LPS.
| LPS and other signalling pathways
As a classical transcription factor, nuclear transcription factor kappa B (NF-κB) activation plays a critical role in LPS-induced VSMCs proliferation. 22 Our previous study has involved the TLR4-mediated NF-κB signalling pathway by microarrays analysis in rats with carotid artery balloon injury. 34 It has been reported that VSMCs proliferation and neointimal formation in balloon-injured rat carotid arteries are associated with activation of cyclin-dependent protein kinases (CDKs) and are cyclin-dependent, 42 suggesting that CDKs regulated proliferative vascular diseases. James 43 
| LPS and phenotypic modulation
Phenotypic modulation of VSMCs from the contractile phenotype to the synthetic phenotype has been shown to be regulated in different stimulations. 44 Bae has described the regulatory mechanism underlying PDGF-induced phenotypic modulation of VSMCs. It has demonstrated that the levels of p-Akt, p-ERK1/2 and p-p38 MAPK are up-regulated after PDGF stimulation in VSMCs, and are significantly reduced by pre-treatment with U0126 (an ERK inhibitor), LY294002
and PD98059 respectively. Pharmacologic inhibition of ERK and Akt blocks PDGF-induced phenotypic modulation of VSMCs. Taken together, PDGF regulates VSMCs phenotypic modulation. 45 We recently published our findings on IRAK4 and modulation of the VSMCs phenotype in diabetic rats. 46 The result showed that an IRAK1/4 inhibitor increased LPS-mediated smooth muscle 22α protein and mRNA expression, which define the contractile phenotype of VSMCs.
Whether or not LPS directly regulates VSMCs phenotypic modulation involved in VSMCs proliferation is unknown.
| LPS and signalling pathways in diabetic rats
We and others have discussed the proliferative effect and underlying mechanism of LPS on VSMCs in non-diabetic rats. A previous study has showed that the circulatory LPS levels and activities were increased in patients with type 2 diabetes. 47 Maria has reported high glucose-induced TLR4 activation in VSMCs. 48 Wang 49 has concluded that TLR4 may become a new potential pharmacological target for treating diabetic retinopathy. Thus, we have detected DNA synthesis and neointimal formation after catheter balloon injury in GotoKakizaki (GK) and matched control Wistar rats. After balloon injury, DNA synthesis and neointimal formation in GK rats were more apparent than in Wistar rats. 34 In a recent study, mesenteric VSMCs were isolated from GK rats and age-matched control Wistar rats. 
| POSSIBLE THERAPEUTIC TARGETS
To date, some experimental animal models and clinical study have suggested that TLRs have a crucial role in cardiovascular diseases.
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A previous study has investigated the role of TLR4 on atherosclerosis stimulated by LPS in ApoE − / − mice and reported that TLR4 may be a therapeutic target in atherosclerosis. Thus, regulation of TLR4 signalling may be a novel therapeutic approach for treating these diseases. 52 However, it remains uncertain whether treatment with a TLR4 inhibitor may attenuate atherosclerosis and proliferative vascular diseases. Because TLR4 is predominated in VSMCs stimulated by LPS, TLR4 has been employed as the primary pharmacological approach in experimental models of VSMCs proliferation and proliferative vascular diseases. Pharmacological approaches of TLR4 signalling inhibition include TLR4 antagonists, neutralizing antibodies, small molecules, natural chemicals and agents. Table 2 summarizes the current applications of TLR 4 inhibition mainly at the experimental level.
| Chemicals
Several studies have been performed using inhibitors of TLR4 activation. TAK-242, a small-molecule agent, has been shown to inhibit LPS-induced inflammation by targeting TLR4 signalling. TAK-242 also inhibits LPS-induced phosphorylation of MAPKs. 53 Ii 54 has examined the therapeutic effect of TAK-242 in a mouse sepsis model. TAK-242 is a promising therapeutic agent for sepsis and immune-mediated lung injury. 55 TAK-242, also known as CLI-095 or resatorvid, is a smallmolecule inhibitor of TLR4 signalling that acts by binding to the intracellular domain of TLR4. Wang examined whether CLI-095 attenuated the progression of atherosclerosis. 56 The results showed that CLI-095 reduced macrophages recruitment to atherosclerotic plaques in vivo and murine peritoneal foam cell formation in vitro. They concluded that CLI-095 was able to alleviate atherosclerotic plaque in ApoE Rapamycin is an important pharmacologic agent against atherosclerosis by inhibiting VSMCs proliferation and neointimal thickening.
It has been reported based on a clinical study that rapamycin inhibits tumour necrosis factor-alpha (TNF-α) production in cultured VSMCs obtained from saphenous vein segments. 60 Therefore, rapamycin may reduce in-stent restenosis via attenuation of inflammatory cytokine expression in VSMCs. Due to the established efficacy in the prevention of stent restenosis, rapamycin might be an interesting therapeutic agent in cardiovascular disorders. However, whether or not rapamycin can directly treat VSMCs proliferation stimulated by LPS needs further investigation.
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Chemicals TAK-242 (CLI-095) A promising therapeutic agent for sepsis 54, 55 Reduces investigate. It will likely be a long time before these agents, who are currently undergoing testing in animal models, enter human trials.
| Clinical drugs
| CONCLUSION AND PERSPECTIVE
Abnormal VSMCs proliferation plays an important role in proliferative vascular diseases, such as atherosclerosis and restenosis, 70 which involve all stages of inflammation associated with complex immune responses. LPS is reported to be involved in the modulation of VSMCs proliferation and neointimal formation. 71 As a TLR4 agonist, LPS is re- 
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